ALKBH5 and neoplasm: Yang et al. (2019) shown that knocking out FTO made melanoma cells hypersensitive to interferon γ (IFN-γ) and PD-1 therapy in melanoma. Li N. et al. (2020) found that in melanoma, colorectal, loss of the m6A demethylase ALKBH5 makes tumors sensitive to cancer immunotherapy by suppressive immune cell accumulation in the tumor microenvironment. Han et al. (2019) found that binding of YTHDF1 to a transcript encoding a lysosomal protease produces an adequate and persistent anti-tumor immune response.